PracticeVideosBlogFlashcardsEspañol
All Practice Exams

Free Practice Questions for Egyptian Board Nephrology

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More Egyptian Board Specialty Certifications (البورد المصري)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Egyptian Board — Anesthesia (Part 1 & 2)

Practice Questions

Egyptian Board — Cardiology (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Infectious Diseases (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Oncology (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Pathology (Part 1 & 2)

Practice Questions

Egyptian Board — Critical Care (Part 1 & 2)

Practice Questions
Exam Review

Key Facts: Egyptian Board Nephrology Exam

Law 12/2022

Governing Legislation (EHC)

Egyptian Health Council

4 Years

Sub-specialty Fellowship Duration

EHC Nephrology Curriculum

3 Parts

Examination Stages (Part 1, Part 2 & Part 3 OSCE)

EHC Regulations

Angoff / Hofstee

Written Standard Setting Method

EHC Assessment Framework

100 MCQs

Curated Study Bank Questions

OpenExamPrep

The Egyptian Board in Nephrology is administered by the Egyptian Health Council under Law 12/2022 and Decree 3798/2023 as a 4-year sub-specialty entered after internal medicine. It comprises Part 1 (renal physiology, glomerular anatomy, acid-base/electrolyte physiology, renal pathology/immunology, renal pharmacology; held March/August), Part 2 (clinical nephrology written MCQ: AKI, CKD-MBD, glomerular diseases, hemodialysis/PD access and complications, renal transplantation, secondary hypertension; held April/September), and Part 3 (clinical OSCE, renal biopsy slide review; held Dec/Jan). This 100-question MCQ bank is an English-language study aid for acid-base interpretation, dialysis prescriptions, and glomerulonephritis management for Part 1 and Part 2; Part 3 is a clinical OSCE.

Sample Egyptian Board Nephrology Practice Questions

Try these sample questions to review concepts for the Egyptian Board Nephrology exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A newborn infant presents at birth with massive proteinuria, profound generalized anasarca, and severe hypoalbuminemia. Genetic analysis confirms a homozygous mutation in the NPHS1 gene located on chromosome 19q13. Which structural podocyte slit diaphragm protein is directly encoded by this gene?
A.Nephrin, a transmembrane cell adhesion protein of the immunoglobulin superfamily
B.Podocin, an integral membrane hairpin protein localized to lipid rafts
C.CD2-associated protein, an adaptor connecting the slit diaphragm to actin
D.Alpha-actinin-4, an actin-filament cross-linking protein of the podocyte cytoskeleton
Explanation: NPHS1 encodes nephrin, a transmembrane protein of the immunoglobulin superfamily that forms the core homophilic and heterophilic zipper-like filtration units of the podocyte slit diaphragm. Mutations in NPHS1 cause Finnish-type congenital nephrotic syndrome, characterized by massive antenatal and neonatal proteinuria.
2A 58-year-old patient with diabetic kidney disease and hypertension is initiated on enalapril. A follow-up serum creatinine reveals a rise from 1.3 mg/dL to 1.5 mg/dL with stable blood pressure. Which hemodynamic alteration at the glomerulus explains this acute, anticipated physiological response?
A.Afferent arteriolar constriction mediated by endothelin-1 activation
B.Efferent arteriolar vasodilation reducing intraglomerular capillary hydrostatic pressure
C.Afferent arteriolar vasodilation increasing renal plasma flow without affecting pressure
D.Efferent arteriolar vasoconstriction increasing filtration fraction and capillary pressure
Explanation: Angiotensin II preferentially constricts the postglomerular efferent arteriole to maintain intraglomerular hydraulic pressure (Pgc). By inhibiting angiotensin II synthesis, ACE inhibitors cause efferent arteriolar vasodilation, lowering Pgc and causing a modest, reversible hemodynamic decline in GFR up to 30%.
3An adult male with type 2 diabetes and chronic kidney disease is prescribed empagliflozin. In which specific anatomical segment of the nephron does this pharmacological agent exert its primary therapeutic action?
A.Distal convoluted tubule luminal apical membrane
B.Thick ascending limb of the loop of Henle basolateral membrane
C.Early proximal convoluted tubule (S1 and S2 segments) luminal brush border
D.Cortical collecting duct principal cell apical membrane
Explanation: Sodium-glucose cotransporter 2 (SGLT2) is a high-capacity, low-affinity transporter located on the apical brush border membrane of the early proximal convoluted tubule (S1 and S2 segments). SGLT2 is responsible for reabsorbing approximately 90% of filtered glucose coupled to sodium.
4A patient with acute angle-closure glaucoma receives intravenous acetazolamide. Examination of the urine confirms marked alkalinization and bicarbonaturia. Through which specific transport mechanism does acetazolamide impair renal bicarbonate reabsorption?
A.Inhibition of the basolateral sodium-bicarbonate cotransporter NBCe1
B.Blockade of the apical pendrin chloride-bicarbonate exchanger in intercalated cells
C.Direct antagonism of apical sodium-hydrogen exchanger 3 (NHE3) phosphorylation
D.Inhibition of luminal carbonic anhydrase IV and intracellular carbonic anhydrase II
Explanation: Acetazolamide is a potent reversible inhibitor of both apical brush-border carbonic anhydrase IV and intracellular carbonic anhydrase II in the proximal convoluted tubule. This prevents the dehydration of luminal carbonic acid and the subsequent intracellular generation of hydrogen and bicarbonate ions, producing self-limited bicarbonaturia.
5A 62-year-old woman with decompensated heart failure is administered intravenous furosemide. Furosemide induces rapid natriuresis and calciuresis by binding to which specific tubular transport complex?
A.Apical Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle
B.Basolateral Na/K-ATPase pump in the medullary collecting duct
C.Apical Na-Cl cotransporter (NCCT) in the distal convoluted tubule
D.Apical Epithelial Sodium Channel (ENaC) in the cortical collecting duct
Explanation: Furosemide reversibly binds to the chloride-binding site of the apical Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. By blocking electroneutral Na-K-2Cl entry, it dissipates the lumen-positive transepithelial potential, which secondarily abolishes paracellular calcium and magnesium reabsorption.
6A 52-year-old man with essential hypertension is treated with hydrochlorothiazide. In addition to mild blood pressure reduction, 24-hour urine collection shows a significant reduction in urinary calcium excretion. What is the primary tubular mechanism underlying this hypocalciuric effect?
A.Stimulation of calcium precipitation by alkaline urine in the medullary collecting duct
B.Enhanced passive and active calcium reabsorption in the proximal and distal convoluted tubules
C.Direct pharmacological opening of basolateral calcium-sensing receptors (CaSR)
D.Suppression of parathyroid hormone secretion leading to diminished bone turnover
Explanation: Thiazides inhibit the apical NCCT cotransporter in the distal convoluted tubule, lowering intracellular sodium and stimulating basolateral 3Na+/Ca2+ exchange, which accelerates apical TRPV5-mediated transcellular calcium entry. Furthermore, volume contraction induces compensatory proximal tubule sodium and passive paracellular calcium reabsorption.
7An 18-year-old patient presents with refractory hypertension, severe hypokalemia, and metabolic alkalosis. Laboratory evaluation reveals suppressed plasma renin activity and undetectable serum aldosterone. Genetic sequencing reveals a mutation in the SCNN1B gene causing deletion of the proline-rich PY motif. What is the molecular consequence of this defect?
A.Constitutive hyperphosphorylation of the mineralocorticoid receptor in principal cells
B.Accelerated lysosomal degradation of ENaC via enhanced binding of the ubiquitin ligase Nedd4-2
C.Failure of Nedd4-2 binding leading to decreased internalization and prolonged membrane retention of ENaC
D.Inhibition of the basolateral Na/K-ATPase leading to intracellular sodium accumulation
Explanation: Liddle syndrome is caused by gain-of-function mutations in the beta or gamma subunits of ENaC (SCNN1B/SCNN1G) deleting the cytoplasmic PY motif. The ubiquitin ligase Nedd4-2 normally binds the PY motif to ubiquitinate ENaC for endocytosis and degradation; loss of this motif results in accumulation of active ENaC channels at the apical membrane.
8A 34-year-old woman with primary Sjogren syndrome presents with recurrent nephrolithiasis, severe muscle weakness, hypokalemia, and hyperchloremic non-anion gap metabolic acidosis with a persistent urine pH of 6.8. A defect in which transport protein located on cortical collecting duct alpha-intercalated cells is responsible?
A.Apical cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel
B.Apical sodium-potassium-2-chloride cotransporter isoform B (NKCC2)
C.Apical sodium-bicarbonate cotransporter NBCn1 (SLC4A7)
D.Apical vacuolar H+-ATPase or basolateral anion exchanger 1 (AE1 / SLC4A1)
Explanation: Classical distal (Type 1) RTA is caused by dysfunction of alpha-intercalated cells in the collecting duct, specifically involving apical vacuolar H+-ATPase, H+/K+-ATPase, or basolateral anion exchanger 1 (AE1/SLC4A1). In auto-immune diseases like Sjogren syndrome, autoantibodies or lymphocytic infiltration disrupt these acid-secreting pumps.
9A 4-year-old child presents with heavy proteinuria, hypoalbuminemia, and generalized edema that fails to achieve remission after 8 weeks of daily oral prednisone. Renal biopsy demonstrates focal segmental glomerulosclerosis. Genetic analysis reveals a homozygous missense mutation in the NPHS2 gene. What is the normal physiological function of the protein product?
A.Scaffolding and anchoring nephrin within cholesterol-rich lipid raft microdomains of the slit diaphragm
B.Acting as the principal extracellular matrix ligand binding glomerular endothelial cells to the GBM
C.Phosphorylating heavy-chain immunoglobulins inside the endoplasmic reticulum of mesangial cells
D.Directly opening apical sodium channels in response to mechanical shear stress in podocyte foot processes
Explanation: NPHS2 encodes podocin, an integral hairpin membrane protein of the stomatin/prohibitin/flotillin family that localizes to lipid rafts at the insertion site of the slit diaphragm. Podocin oligomerizes to form scaffolding microdomains that recruit and stabilize nephrin and CD2AP at the podocyte plasma membrane.
10During experimental perfusion of the single nephron, an increase in sodium chloride delivery to the macula densa elicits a prompt decline in single-nephron glomerular filtration rate (SNGFR). Which signaling cascade mediates this tubuloglomerular feedback (TGF) response?
A.Release of nitric oxide from macula densa causing selective afferent arteriolar dilation
B.NaCl uptake via apical NKCC2 stimulating basolateral ATP/adenosine release to activate vascular A1 receptors
C.PGE2 secretion from macula densa stimulating renin exocytosis from juxtaglomerular granular cells
D.Direct entry of chloride into juxtaglomerular cells through CFTR activating endothelin-B receptors
Explanation: In tubuloglomerular feedback (TGF), elevated luminal NaCl concentration enhances uptake by apical NKCC2 cotransporters in macula densa cells. This increases basolateral ATP release, which is rapidly hydrolyzed to adenosine; adenosine acts on vascular A1 receptors on the afferent arteriole to elevate cytosolic calcium, causing afferent vasoconstriction and reducing GFR.

About the Egyptian Board Nephrology Exam

The Egyptian Board in Nephrology (أمراض الكلى) is the official national postgraduate medical qualification awarded by the Egyptian Health Council (EHC), established pursuant to Law No. 12 of 2022 and its Executive Regulations (Decree No. 3798 of 2023), consolidating and replacing the former Egyptian Fellowship (الزمالة المصرية). The program is an accredited 4-year sub-specialty entered after internal medicine core training, encompassing renal physiology, glomerular diseases, acute kidney injury, chronic kidney disease, dialysis, and renal transplantation. Important disclosure: Part Three is a dedicated OSCE clinical examination involving real patient encounters, clinical stations, and renal biopsy slide reviews; this 100-question multiple-choice question bank is an English-language study aid for acid-base interpretation, dialysis prescriptions, and glomerulonephritis management for Part One and Part Two—it is not a clinical OSCE simulation or a substitute for hands-on clinical fellowship training.

Exam sponsor: Egyptian Health Council (EHC) — Egyptian Board (المجلس الصحي المصري — البورد المصري). The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The Egyptian Board in Nephrology features a three-part assessment structure governed by the Egyptian Health Council: Part One is a written MCQ examination focusing on applied basic sciences (renal physiology, glomerular anatomy, acid-base and electrolyte physiology, renal pathology/immunology, renal pharmacology) held twice yearly in March and August. Part Two is a written MCQ examination focusing on clinical nephrology (acute kidney injury [KDIGO], chronic kidney disease and mineral-bone disorder, glomerular diseases, hemodialysis and peritoneal dialysis access and complications, renal transplantation and immunosuppression, secondary hypertension, tubulointerstitial diseases) held twice yearly in April and September. Part Three is an annual practical/clinical examination (held in December/January) consisting of OSCE stations, renal biopsy slide review, and clinical stations.

Time Limit

Varies by examination part

Passing Score

Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published

Exam / Certification Fees

Prescribed by Egyptian Health Council regulatory bylaws

Exam sponsor website

Reported exam pass rate: Determined by psychometric standard-setting per diet. Written examination cut scores (Part One and Part Two) are calculated using criterion-referenced standard-setting procedures (Angoff, Modified Angoff, or Hofstee). The Part Three clinical exam uses the Borderline Regression Method. There is no static passing percentage published. Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

20%

Renal Physiology, Tubular Transport & Glomerular Anatomy

Glomerular filtration dynamics, tubuloglomerular feedback, proximal tubule transport, loop of Henle countercurrent mechanisms, distal convoluted tubule and collecting duct transport, and podocyte/endothelial anatomy.

20%

Acid-Base, Fluid & Electrolyte Disorders

Metabolic acidosis and alkalosis, anion gap, Stewart physicochemical approach, renal tubular acidoses (Types 1, 2, 4), potassium disorders, sodium/water balance (hyponatremia, SIADH, CSW, diabetes insipidus), and divalent ion homeostasis.

20%

Glomerular Diseases, Nephrotic/Nephritic Syndromes & Renal Pathology

Minimal change disease, FSGS, membranous nephropathy, IgA nephropathy, lupus nephritis (ISN/RPS classes), ANCA-associated vasculitis, anti-GBM disease, MPGN/C3 glomerulopathy, thrombotic microangiopathies, and immunofluorescence/EM interpretation.

20%

Acute Kidney Injury, CKD Progression & Secondary Hypertension

KDIGO criteria for AKI, cardiorenal and hepatorenal syndromes, urinary sediment interpretation, CKD staging and slowing progression (SGLT2i, nsMRA, RAASi), anemia of CKD, CKD-MBD (FGF23, PTH, Klotho), and renovascular/endocrine hypertension.

20%

Dialysis Modalities, Access Complications & Kidney Transplantation

Hemodialysis adequacy (Kt/V, URR), vascular access types and complications (AV fistula thrombosis, steal syndrome), peritoneal dialysis kinetics (PET test, adequacy, peritonitis), CRRT prescriptions and regional citrate anticoagulation, pre-transplant immunology (HLA, PRA, crossmatch), immunosuppressive protocols, rejection types, and post-transplant infections/malignancies.

Preparing for the Egyptian Board Nephrology Exam

What You Need to Know

  • Passing score: Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published
  • Assessment: The Egyptian Board in Nephrology features a three-part assessment structure governed by the Egyptian Health Council: Part One is a written MCQ examination focusing on applied basic sciences (renal physiology, glomerular anatomy, acid-base and electrolyte physiology, renal pathology/immunology, renal pharmacology) held twice yearly in March and August. Part Two is a written MCQ examination focusing on clinical nephrology (acute kidney injury [KDIGO], chronic kidney disease and mineral-bone disorder, glomerular diseases, hemodialysis and peritoneal dialysis access and complications, renal transplantation and immunosuppression, secondary hypertension, tubulointerstitial diseases) held twice yearly in April and September. Part Three is an annual practical/clinical examination (held in December/January) consisting of OSCE stations, renal biopsy slide review, and clinical stations.
  • Time limit: Varies by examination part
  • Exam / certification fees: Prescribed by Egyptian Health Council regulatory bylaws Official sources

Using Our Practice Resources

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

Egyptian Board Nephrology: Suggested Study Strategy

1Master renal physiology calculations: clearance equations, fractional excretion of sodium/urea, trans-tubular potassium gradient (TTKG), and free water clearance.
2Systematically approach acid-base disorders using the 4-step physiological method and the Stewart physicochemical approach (strong ion difference, total non-volatile weak acids, and pCO2).
3Memorize characteristic light, immunofluorescence, and electron microscopy findings for glomerular diseases (e.g., subepithelial spikes in PLA2R membranous, subendothelial humps in post-infectious GN, dense deposits in C3G).
4Understand the modern pharmacotherapy of CKD progression: SGLT2 inhibitors (EMPA-KIDNEY, DAPA-CKD), non-steroidal mineralocorticoid receptor antagonists (finerenone), and dual endothelin-angiotensin receptor antagonists.
5Review renal replacement therapy mechanics: hemodialysis urea kinetics (single-pool Kt/V), peritoneal equilibration test (PET) D/P creatinine interpretation, and regional citrate anticoagulation protocols in CRRT.
6Learn kidney transplantation protocols: desensitization, induction therapy (thymoglobulin vs. basiliximab), calcineurin inhibitor toxicity vs. T-cell/antibody-mediated rejection (Banff criteria), and BK virus nephropathy management.

Frequently Asked Questions

What is the governing authority of the Egyptian Board in Nephrology?

The Egyptian Board (البورد المصري) is governed by the Egyptian Health Council (EHC / المجلس الصحي المصري), established pursuant to Law No. 12 of 2022 and Prime Ministerial Decree No. 3798 of 2023. It unifies national postgraduate medical certification, replacing the former Egyptian Fellowship (الزمالة المصرية).

What is the training duration and prerequisite for the Nephrology Board?

Nephrology is an accredited 4-year sub-specialty training program entered following the successful completion of core internal medicine residency training and full registration with the Egyptian Medical Syndicate.

What is the structure of the Egyptian Board Nephrology examinations?

The examination comprises three parts: Part One is a written MCQ examination covering applied basic sciences (renal physiology, tubular transport, acid-base physiology, renal pathology, and pharmacology) held twice yearly in March and August. Part Two is a written MCQ examination in advanced clinical nephrology (AKI, CKD-MBD, glomerular diseases, dialysis, and transplantation) held twice yearly in April and September. Part Three is an annual practical/clinical examination held in December/January featuring OSCE stations, clinical encounters, and renal biopsy slide reviews.

What passing standard is applied to the written examinations?

Pass marks are not fixed static percentages. The Egyptian Health Council utilizes psychometric standard-setting methodologies (Angoff, Modified Angoff, or Hofstee) to determine the passing cut score for each written diet. Part Three clinical OSCE stations utilize the Borderline Regression Method.

Does this question bank prepare for the Part Three clinical examination?

Part Three is a hands-on clinical OSCE involving real patient encounters, clinical stations, and microscopic renal biopsy slide reviews. This 100-question practice MCQ bank is an English-language study aid specifically curated for acid-base interpretation, dialysis prescriptions, and glomerulonephritis management in Part One and Part Two; it does not replace hands-on clinical fellowship training or OSCE stations.

What are the core clinical topics covered in Part Two?

Part Two covers acute kidney injury (KDIGO criteria), chronic kidney disease progression and mineral-bone disorder (CKD-MBD), primary and secondary glomerular diseases, hemodialysis and peritoneal dialysis access and complications, kidney transplantation immunology and immunosuppression, secondary hypertension, and tubulointerstitial nephritis.